Charlotte Jeanneau | Drug Delivery | Best Researcher Award

Published on by Applied Scientist

Best Researcher Award

Charlotte Jeanneau
Université de Tours

Charlotte Jeanneau
Affiliation Université de Tours
Country France
Scopus ID 6701451744
Documents 56
Citations 3,238
h-index 27
Subject Area Drug Delivery
Event Applied Scientist Awards

Charlotte Jeanneau is a researcher affiliated with Université de Tours whose documented research profile is associated with the field of Drug Delivery. The supplied bibliometric record identifies 56 documents, 3,238 citations, and an h-index of 27 under Scopus Author ID 6701451744. These indicators provide a quantitative view of indexed research activity and citation impact, while the scope and significance of individual contributions require consideration of the underlying publications and their scientific context.[1]

Abstract

This article presents an academic recognition profile for Charlotte Jeanneau, affiliated with Université de Tours and associated with the research area of Drug Delivery. The supplied Scopus information records 56 documents, 3,238 citations, and an h-index of 27. Such bibliometric measures are commonly used to describe aspects of scholarly productivity and citation visibility, although they should be interpreted alongside publication quality, research relevance, methodological contribution, collaboration, and broader scientific influence.[1] Drug delivery research encompasses the development and evaluation of approaches intended to transport therapeutic agents to appropriate biological sites while addressing issues such as stability, bioavailability, targeting, controlled release, and safety.[2]

Keywords

Drug Delivery; Pharmaceutical Sciences; Therapeutic Delivery Systems; Drug Delivery Technologies; Nanomedicine; Research Impact; Biomedical Research

Introduction

Drug delivery is an interdisciplinary research area connecting pharmaceutical science, chemistry, materials science, biology, medicine, and engineering. Modern drug delivery systems seek to improve how therapeutic compounds are administered, distributed, released, and made available at their intended biological targets. Research in this field includes conventional formulation approaches as well as advanced carriers, controlled-release systems, nanostructured platforms, and targeted delivery strategies.[2][4]

Research Profile

The supplied academic information identifies Charlotte Jeanneau with Université de Tours and the subject area of Drug Delivery. The Scopus identifier associated with the profile is 6701451744. According to the supplied bibliometric record, the profile contains 56 indexed documents, 3,238 citations, and an h-index of 27.[1][2]

Research Contributions

The research area associated with this profile, Drug Delivery, addresses the scientific challenge of delivering therapeutic substances with appropriate spatial and temporal control. Important research directions in the discipline include improving drug solubility and stability, regulating release kinetics, developing carrier systems, enhancing biological availability, and reducing unintended exposure. Contemporary approaches also examine how physicochemical properties of delivery materials influence biological interactions and therapeutic performance.[5][3] Lipid nanoparticles represent another important delivery technology, particularly in the development of nucleic-acid-based therapeutics and related biomedical applications.[4]

Publications

The supplied Scopus record reports 56 documents for the researcher profile identified by Author ID 6701451744.[1] A complete publication-level assessment would require examination of the individual indexed records, including article titles, journals, publication years, author contributions, citation distributions, and subject classifications. Because those individual publication records were not supplied as part of the input data, this profile does not attribute specific publications to Charlotte Jeanneau beyond the provided aggregate Scopus information.[4]

Research Impact

The supplied bibliometric indicators report 3,238 citations and an h-index of 27 across 56 documents in the identified Scopus profile.[1] Citation counts can provide evidence of how frequently indexed publications have been cited within the scholarly literature, while the h-index combines publication and citation information into a single measure. These metrics are database-dependent and may vary with indexing coverage, author disambiguation, citation updates, and the date on which the profile is examined.

Award Suitability

The Best Researcher Award profile is based on the supplied affiliation, research subject area, and Scopus bibliometric record. The reported combination of 56 documents, 3,238 citations, and an h-index of 27 provides quantitative information that can form part of an academic recognition assessment.[1] A complete award evaluation may additionally consider the originality and significance of research contributions, publication quality, scholarly leadership, collaboration, research continuity, and evidence of broader scientific or societal relevance.

Conclusion

Charlotte Jeanneau, affiliated with Université de Tours, is presented in this academic recognition profile as a researcher associated with Drug Delivery. The supplied Scopus information records 56 documents, 3,238 citations, and an h-index of 27 under Author ID 6701451744.[1] Drug Delivery is a multidisciplinary field concerned with developing scientifically controlled approaches for transporting therapeutic agents and improving their delivery characteristics.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Charlotte Jeanneau, Author ID 6701451744. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6701451744
  2. T Giraud, C Jeanneau, I About. (2026). Anti-inflammatory potential of a New Calcium Silicate based Endodontic Sealer.
    https://www.sciencedirect.com/science/article/pii/S0099239926003596
  3. C Le Fournis, T Giraud, S Roumani, C Jeanneau, I About. (2026). Macrophage‐Pulp Fibroblast Interactions Modulate Initial Dental Pulp Regeneration In Vitro.
    https://onlinelibrary.wiley.com/doi/abs/10.1111/iej.70103
  4. A Cotten, C Jeanneau, P Decherchi, I About. (2024). Complement C5a Implication in Axonal Growth After Injury.
    https://www.mdpi.com/2073-4409/13/20/1729
  5. C Jeanneau, JH Catherine, T Giraud, R Lan, I About. (2024). The Added Value of a Collagenated Thermosensitive Bone Substitute as a Scaffold for Bone Regeneration.
    https://www.mdpi.com/1996-1944/17/3/625

Sutha Devaraj | Drug Discovery | Research Excellence Award

Published on by Applied Scientist

Research Excellence Award

Sutha Devaraj
Perdana University, Malaysia

Sutha Devaraj
Affiliation Perdana University
Country Malaysia
Scopus ID 36339229200
Documents 14
Citations 191
h-index 6
Subject Area Drug Discovery
Event Applied Scientist Awards
ORCID 0000-0003-0092-840X

Sutha Devaraj, affiliated with Perdana University in Malaysia, is associated with research in drug discovery, a multidisciplinary field that integrates medicinal chemistry, pharmacology, molecular biology, computational approaches, and related biomedical sciences. Available bibliographic information records 14 documents, 191 citations, and an h-index of 6, providing a quantitative basis for considering the researcher’s publication activity and scholarly visibility. The Research Excellence Award recognizes sustained scholarly contributions, research productivity, and measurable impact within a defined field of scientific inquiry. [1]

Abstract

Sutha Devaraj is a researcher affiliated with Perdana University, Malaysia, whose scholarly profile is associated with the field of drug discovery. Drug discovery research encompasses the identification, validation, optimization, and evaluation of therapeutic candidates and increasingly relies on interdisciplinary methods spanning molecular sciences, computational analysis, pharmacology, and biomedical research.[2] The researcher’s recorded bibliometric profile includes 14 documents, 191 citations, and an h-index of 6. These indicators, considered alongside the relevance of the subject area and the broader scientific importance of therapeutic discovery, provide a basis for evaluating research productivity and academic contribution.[1]

Keywords

Sutha Devaraj; Research Excellence Award; drug discovery; medicinal chemistry; pharmacology; therapeutic development; biomedical research; pharmaceutical science; research impact; Perdana University; Malaysia.

Introduction

Drug discovery is a complex scientific process involving the exploration of biological mechanisms, identification of molecular targets, design or screening of candidate compounds, and subsequent assessment of their biological and pharmacological properties. Contemporary approaches increasingly combine experimental and computational techniques to improve the efficiency of candidate identification and optimization.[2][3]

Research Profile

Sutha Devaraj is affiliated with Perdana University in Malaysia and is identified with the subject area of drug discovery. The available scholarly record reports 14 documents, 191 citations, and an h-index of 6. These metrics indicate an established publication record and measurable citation activity within the indexed research literature.[1]

Research Contributions

Research in drug discovery contributes to the broader development of therapeutic science by addressing the identification and refinement of compounds or biological approaches with potential pharmacological value. The field is inherently interdisciplinary and may incorporate chemical synthesis, structure–activity relationship analysis, molecular modeling, biological screening, pharmacological evaluation, and related analytical methodologies.[2][3]

  • Contribution to scholarly research associated with drug discovery and related biomedical sciences.
  • Development and dissemination of research through peer-reviewed academic publications.
  • Participation in the broader scientific knowledge base through research outputs that have received measurable citation activity.
  • Potential interdisciplinary relevance to pharmaceutical science, therapeutic research, and associated areas of biomedical investigation.

Publications

The indexed research profile associated with Sutha Devaraj records 14 documents. The publication record may be examined through established scholarly databases to assess individual research outputs, co-authorship patterns, subject classifications, citation relationships, and publication venues.[1][4]

Research Impact

The reported citation count of 191 and h-index of 6 provide quantitative indicators of the visibility of the researcher’s indexed scholarly work. Citation metrics are commonly used to examine patterns of scholarly recognition, but their interpretation should account for differences between disciplines, publication practices, career stages, and research communities.[3]

Award Suitability

The available academic profile provides several elements relevant to consideration for a Research Excellence Award. These include an identifiable research specialization in drug discovery, an affiliation with Perdana University, a documented indexed publication record, and measurable citation activity. Together, these factors provide a structured foundation for evaluating scholarly productivity and research visibility.[1]

Conclusion

Sutha Devaraj of Perdana University, Malaysia, is associated with research in drug discovery and has a documented scholarly profile comprising 14 indexed documents, 191 citations, and an h-index of 6. The combination of subject-area relevance, publication activity, citation visibility, and persistent researcher identification provides a basis for academic recognition and further evaluation within the context of research excellence. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Sutha Devaraj, Author ID 36339229200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=36339229200
  2. S Devaraj, MA Rashid. (2026). Inflammatory Cytokine Profiles as Predictors of Neonatal Respiratory Morbidity.
    https://ajcppb.com/index.php/ajcppb/article/view/8
  3. S Devaraj, S Ismail, et al. (2010). Evaluation of the hepatoprotective activity of standardized ethanolic extract of Curcuma xanthorrhiza Roxb.
    https://www.academia.edu/download/110942056/682C41521571.pdf
  4. TY Lee, Sutha D, et al. (2023). Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    https://www.sciencedirect.com/science/article/pii/S0024320523000437
  5. MHM Nazmul, S Devaraj, et al. (2025). Bioaccumulation of heavy metals in aquatic organisms and its effects on human consumption.
    https://www.sid.ir/paper/1915108/en

Njayou Frederic Nico | Drug Discovery | Best Researcher Award

Published on by Applied Scientist

Prof. Njayou Frederic Nico | Drug Discovery | Best Researcher Award

Researcher |University of Yaounde 1 | Cameroon

Prof. Njayou Frederic Nico, is a Full Professor of Biochemistry, Pharmacology, and Toxicology at the University of Yaounde I, where he has built an outstanding career in scientific research, teaching, and community development. His expertise spans the study and valorization of medicinal plants and wild mushrooms for the treatment of inflammatory, parasitic, viral, bacterial, and neurological diseases, including hepatitis, gastric ulcer, malaria, Alzheimer’s, and Parkinson’s disease. He has made significant contributions through in vitro and in vivo studies using chemistry, molecular biology, enzymology, and biochemistry tools, leading to the discovery of several plant and mushroom species with strong therapeutic potential. A Fulbright Visiting Scholar at the University of Connecticut (2012–2013), he gained advanced training in cell culture, western blotting, and PCR, which enhanced his capacity to conduct high-quality research. He has supervised numerous Master’s and PhD theses, published widely, and contributed to innovation, including the development of improved traditional medicines and cosmetics. Beyond academia, he is engaged in training communities on sustainable harvesting and health awareness. His scientific output includes 311 citations from 35 indexed documents with an h-index of 11, underscoring his impact in pharmacology and biochemistry research.

Profile : Scopus | ORCID

Featured Publications

  • Magoudjou Pekam, J. N., Efange, N. M., Mishro, L., Keumoe, R., Ndjakou, B. L., Ayong, L., Njayou, F. N., Moundipa, P. F., & Rajendran, V. (2025). In vitro antiplasmodial activities of extracts and fractions from Lepidobotrys staudtii against sensitive and resistant blood-stage parasites of Plasmodium falciparum. International Journal for Parasitology: Drugs and Drug Resistance.

  • Fils Armand Ella, A., Dupon Akamba Ambamba, B., Njayou, F. N., & Moundipa, P. F. (2025). Khaya grandifolia exerts multitarget neuroprotective potential against neurodegenerative disorders: In vitro and in silico studies. IBRO Neuroscience Reports, 19, 400–408.

  • Tchana, J. C. T., Ayissi Owona, B., Messi, N. A., Kouam Kamgue, T. N., Sebdou, A., Ngoungoure Ndam, V., Kouamo, M. M. F., Njayou, F. N., & Moundipa, P. F. (2025). Effects of Garcinia Manni Oliv. biflavonoids on a model of aluminum chloride (AlCl3)-induced Alzheimer’s disease in Drosophila. International Journal of Biochemistry Research & Review, 34(4), 369–388.

  • Deussom, P. M., Ewonkem, M. B., Enang, B., Kamdem, M. H. K., Mbock, M. A., Fotsing, M. C. D., Ndinteh, D. T., Njayou, F. N., & Toze, F. A. (2025). Synthesis and biological evaluation of esterified anti-inflammatory drugs with ethylene glycol linkers: Cytotoxicity, anti-inflammatory and antioxidant properties. Royal Society Open Science, 12, 241413.

  • Ngohoba, V. S., Pechangou, N. S., Njayou, F. N., & Moundipa, P. F. (2025). Therapeutic targets associated with medical research in the treatment of inflammatory bowel disease. medtigo JPharmacol, 1(1), e14202205.

Bonewendé Mohamed Belemlilga | Drug Development | Best Researcher Award

Published on by Applied Scientist

Dr. Bonewendé Mohamed Belemlilga | Drug Development | Best Researcher Award

Reseacher at Institut de Recherche en Sciences de la Sante, Burkina Faso

Bonewendé Mohamed BELEMLILGA is a distinguished Burkinabè research associate specializing in Animal Pharmacology and Physiology at the Institut de Recherche en Sciences de la Santé (IRSS/CNRST). With a career marked by extensive contributions to ethnopharmacology, phytomedicine development, and preclinical drug evaluation, he has become a central figure in advancing traditional medicine through scientific validation in Burkina Faso and across West Africa. His leadership extends to key roles such as Head of the Research and Evaluation Department at IRSS and editorial board member for the Science de la Santé journal. He is also actively involved in national research strategy formulation, having served on committees crafting the CNRST’s 2025–2029 strategic research plan. Dr. BELEMLILGA’s expertise is further reflected in over 50 peer-reviewed publications focusing on pharmacological studies, toxicity assessments, and the pharmacodynamic properties of medicinal plants. His dedication to bridging traditional knowledge and modern science has led him to coordinate and participate in several national and international research projects, educational programs, and clinical investigations. With a solid background in both experimental research and academic supervision, he represents a dynamic blend of scholarly depth, technical skill, and visionary research leadership in African health science innovation.

Professional Profile

Education

Dr. Bonewendé Mohamed BELEMLILGA pursued his higher education at the University of Ouagadougou, where he demonstrated a consistent commitment to excellence in health and biological sciences. He obtained his Bachelor’s degree in Biological Sciences in 2007, followed by a Master’s degree in Biological Sciences with a specialization in Animal Biology and Physiology in 2008. He then advanced to complete a DEA (Diplôme d’Études Approfondies) in Applied Pharmacology and Toxicology from the UFR-SDS in 2011, achieving honors for his academic performance. His doctoral studies culminated in a Ph.D. in Applied Pharmaceutical Sciences, with a specialization in Applied Pharmacology, awarded by the Doctoral School of Health in 2019. His dissertation focused on the pharmacological and phytochemical properties of Saba senegalensis, a plant traditionally used to treat parasitic infections. This strong academic foundation equipped Dr. BELEMLILGA with the skills necessary for rigorous scientific research in pharmacology and ethnomedicine. In addition, his multilingual proficiency in French and English and his strong computer skills enhance his ability to operate effectively in both national and international academic settings. His academic path reflects a deep-seated dedication to public health through biomedical innovation.

Professional Experience

Dr. BELEMLILGA’s professional journey is marked by a rich tapestry of research, teaching, and leadership roles. Since 2020, he has served as a research associate in Animal Pharmacology-Physiology at IRSS/CNRST, while also heading the Research and Evaluation Department since January 2024. He has been instrumental in multiple strategic planning committees, including the Commission for Research and Innovation, the CNRST’s disciplinary board, and the drafting of national research strategies for 2025–2029. As a temporary lecturer at Université Saint Thomas d’Aquin, he has also been active in academic mentorship, supervising multiple master’s and doctoral theses. His expertise has been recognized internationally, exemplified by training certifications in Good Clinical Practice (ICH E6 R2), clinical research, and laboratory quality systems. Dr. BELEMLILGA has coordinated numerous clinical and pharmacological projects, notably on phytomedicines for gastrointestinal and respiratory illnesses. His fieldwork includes internships and collaborative research across France, Côte d’Ivoire, and Ghana. He is a founding member of the Société de Pharmacologie et Toxicologie du Burkina (SOPHATOX-B) and a contributor to numerous workshops and training programs. Through these roles, he has demonstrated an unwavering commitment to evidence-based health science rooted in traditional knowledge.

Research Interest

Dr. BELEMLILGA’s research interests lie at the dynamic intersection of ethnopharmacology, parasitology, toxicology, and pharmacognosy. His central scientific pursuit focuses on validating traditional medicinal practices by elucidating the pharmacological properties of plant-based therapies used in Burkina Faso and West Africa. With a special emphasis on parasitic diseases and gastrointestinal infections, he has conducted extensive in vitro and in vivo experiments to evaluate antipyretic, anti-inflammatory, analgesic, antioxidant, and anthelmintic activities of natural plant extracts. Plants like Saba senegalensis, Balanites aegyptiaca, and Gomphrena serrata are frequently featured in his studies. His research also involves toxicological screening to ensure the safety of phytomedicines intended for human or veterinary use. In recent years, Dr. BELEMLILGA has expanded his interest into clinical trial design, especially in the context of plant-based antimalarial and anti-parasitic formulations. He is also actively engaged in capacity building and promoting best practices in traditional medicine production and usage. His research aims to bridge the gap between indigenous healing systems and modern biomedicine, contributing to global health initiatives through culturally grounded scientific innovation.

Research Skills

Dr. BELEMLILGA has cultivated a robust set of interdisciplinary research skills that underpin his expertise in ethnopharmacology and biomedical sciences. His core competencies include phytochemical screening, bioassay-guided fractionation, pharmacodynamic and toxicological testing of natural extracts, and the standardization of phytomedicines. He is well-versed in both qualitative and quantitative experimental techniques, ranging from in vivo efficacy trials to molecular analytical methods such as chemical profiling via molecular networking. His hands-on experience includes high-level laboratory procedures, animal experimentation, and clinical trial coordination adhering to international GCP standards. Dr. BELEMLILGA is proficient in project management, having led and contributed to multiple funded research initiatives across Africa and Europe. He is also skilled in academic writing and peer-review processes, serving as an excellent reviewer for several scientific journals. As a scientific trainer and lecturer, he has transferred knowledge to students and health professionals through numerous workshops, including those hosted by the WHO-TDR and local universities. His ability to design, implement, and evaluate complex biomedical studies places him at the forefront of research promoting safe and effective traditional medicine integration.

Awards and Honors

Dr. BELEMLILGA’s contributions have been acknowledged through numerous awards, certifications, and prestigious appointments. In 2022 and 2023, he was recognized with the Certificate of Excellence for his role as a peer reviewer in leading scientific journals. His leadership in the IRSS/CNRST has earned him positions on key national committees, such as the Commission for Research and Innovation and the Editorial Board of Sciences et Technique. He has received multiple certifications from renowned organizations like WHO-TDR and the Global Health Network, reflecting international recognition of his expertise in clinical research and pharmacological evaluation. As a founding member of SOPHATOX-B and a certified trainer in ethnopharmacology, Dr. BELEMLILGA has significantly contributed to capacity-building initiatives across West Africa. His scientific publications have garnered citations and respect within the fields of traditional medicine and drug development. His work has not only influenced policy frameworks in Burkina Faso but has also enhanced the global visibility of African medicinal plant research. These accolades underscore his commitment to excellence, collaboration, and innovation in public health research and education.

Conclusion

Dr. Bonewendé Mohamed BELEMLILGA exemplifies a new generation of African researchers bridging traditional medicine with modern pharmacological science. With a career grounded in rigorous education and enriched by international collaborations, he continues to push the boundaries of phytomedicine research in West Africa. His work has had a tangible impact on both policy and practice, particularly in the validation and clinical assessment of indigenous medicinal formulations. As a research associate, academic mentor, strategic planner, and scientific communicator, he has made enduring contributions to the biomedical landscape in Burkina Faso and beyond. His dedication to interdisciplinary research, ethical scientific practice, and public health empowerment demonstrates a holistic vision for African health innovation. Through an impressive portfolio of publications, funded projects, and leadership roles, Dr. BELEMLILGA is shaping the future of pharmacological research rooted in cultural relevance and scientific integrity. His continued efforts promise to yield new therapies, foster research capacity, and inspire the next generation of scholars committed to sustainable, evidence-based healthcare solutions in Africa and globally.

Publications Top Notes

  1. chemical analysis by molecular networking methods on extracts of saba senegalensis and its anthelmintic activity on caenorhabditis elegans
    Authors: Mohamed B. Belemlilga, Hazrina Hazni, Aristide Traore, Indira Dennemont, Sébastien Pomel, Sandrine Cojean, Mehdi A. Beniddir, Sylvin Ouedraogo, Christian Bories, Philippe M. Loiseau
    Year: 2025

  2. evaluation of anti-inflammatory activities and acute toxicity of the leaves aqueous macerate of boscia senegalensis
    Authors: Mohamed B. Belemlilga, Mathieu Nitiema, Aristide Traore, Eric Nanema, Souleymane Compaore, G. Geoffroy Ouedraogo, Sylvain Ilboudo, Lazare Belemnaba, Noufou Ouedraogo, Félix B. Kini
    Year: 2025

  3. toxicity assessment of a phytomedicine based on an almond extract from the fruit of balanites aegyptiaca intended for helminthiases care in burkina faso
    Authors: G. G. Ouedraogo, M. B. Belemlilga, T. Kouguilima, G. D. Somda, S. Ilboudo, S. Ouedraogo, A. Traore, L. Belemnaba, F. B. Kini, S. Ouedraogo
    Year: 2025

  4. acute toxicity and anthelmintic effects of gomphrena serrata extracts on adult worms and eggs of haemonchus contortus
    Authors: H. Ouedraogo, M. B. Belemlilga, A. Traore, G. A. L. Boly, F. Moyenga, G. G. Ouedraogo, S. Ilboudo, L. Belemnaba, S. Ouedraogo
    Year: 2024

  5. antibacterial, anti-inflammatory and antioxidant activities of an acazy herbal formula used in traditional medicine to treat respiratory infections
    Authors: M. B. Belemlilga, B. Bayala, G. A. L. Boly, M. A. Ouédraogo, A. R. Boina, B. Yaro, F. Badea, C. Diguti, M. Koala, D. P. Ilboudo, et al.
    Year: 2024

  6. optimization and standardization of the extraction method of balanites aegyptiaca seeds used in the formulation of an antiparasitic phytomedicine
    Authors: M. B. Belemlilga, S. Ouedraogo, G. A. L. Boly, D. H. Dao, J. T. Coulibaly, J. C. R. P. Ouedraogo, S. Compaoré, S. Traore, M. Koala, E. N. H. Youl
    Year: 2024

  7. evaluation of acute and subacute toxicity and sedative effect of feretia apodanthera leaves
    Authors: A. S. Silue, S. Ilboudo, T. A. Djadji, G. Ouedraogo, M. B. Belemlilga, G. Kouakou-Siransy, R. Semdé
    Year: 2024

  8. phytochemical profile, acute toxicity, antioxidant and anti-inflammatory activity of hydroethanolic extracts from odontonema strictum root and stem
    Authors: M. Nitiema, L. Belemnaba, C. W. R. Ouedraogo, M. B. Belemlilga, S. Ouedraogo, M. Koala, A. Traore, J. F. Aïkpe, N. Ouedraogo, F. B. Kini
    Year: 2024

  9. phytochemical and in vitro anthelmintic properties of mesocarp of fruit extracts from balanites aegyptiaca
    Author: Mohamed Bonewendé Belemlilga
    Year: 2024